Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B

Lai, Ching‐Lung; Shouval, Daniel; S. Lok, Anna; Chang, Ting‐Tsung; Cheinquer, Hugo; Goodman, Zachary; DeHertogh, Deborah; B. Wilber, Richard; C. Zink, Richard; Cross, Anne; J. Colonno, Richard; Fernandes, Lori

doi:10.1056/nejmoa051287

Public

Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B

Published in New England Journal of Medicine • Mar 8, 2006

Authors:

Ching‐Lung Lai

Daniel Shouval

Anna S. Lok

Abstract

BACKGROUND: Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. METHODS: In this phase 3, double-blind trial, we randomly assigned 648 patients with HBeAg-negative chronic h...

Subject

Entecavir

Lamivudine

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!